@article {Romano2020.08.10.20171397, author = {Stefano Romano and George M. Savva and Janis R. Bedarf and Ian G. Charles and Falk Hildebrand and Arjan Narbad}, title = {Meta-analysis of the gut microbiome of Parkinson{\textquoteright}s disease patients suggests alterations linked to intestinal inflammation}, elocation-id = {2020.08.10.20171397}, year = {2020}, doi = {10.1101/2020.08.10.20171397}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The gut microbiota is emerging as an important modulator of neurodegenerative diseases, and accumulating evidence has linked gut microbes to Parkinson{\textquoteright}s disease (PD) symptomatology and pathophysiology. PD is often preceded by gastrointestinal symptoms and alterations of the enteric nervous system accompany the disease. Several studies have analyzed the gut microbiome in PD, but a consensus on the features of the PD-specific microbiota is missing. Here, we conduct a meta-analysis re-analyzing 10 currently available 16S microbiome datasets to investigate whether underlying alterations in the gut microbiota of PD patients exist. We found consistent alterations in PD-associated microbiome, which are significant and robust to confounders across studies, although differences in microbiome structure between PD and controls are limited. Enrichment of the genera Lactobacillus, Akkermansia, and Bifidobacterium and depletion of bacteria belonging to the families Lachnospiraceae and Ruminococcaceae, which are important short-chain fatty acids producers, emerged as the most consistent PD gut microbiome alterations. This dysbiosis might result in a pro-inflammatory status which could explain the recurrent gastrointestinal symptoms affecting PD patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported in part by the NBI Computing infrastructure for Science (CiS) group through access to High-Performance Computing infrastructures. The authors gratefully acknowledge the support of the Biotechnology and Biological Sciences Research Council (BBSRC); this research was funded by the BBSRC Institute Strategic Programme Gut Microbes and Health BB/R012490/1 and its constituent project BBS/E/F/000PR10356. GS was supported by the BBSRC Core Capability Grant BB/CCG1860/1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB and/or ethics committee approvals requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are attached to the manuscript}, URL = {https://www.medrxiv.org/content/early/2020/08/12/2020.08.10.20171397}, eprint = {https://www.medrxiv.org/content/early/2020/08/12/2020.08.10.20171397.full.pdf}, journal = {medRxiv} }